For the latest COVID information Click Here.
Updated July 2021
Guselkumab belongs to a class of medicines called biological disease modifying antirheumatic drugs (biological DMARDs or bDMARDs). Specifically, it is a monoclonal antibody which works by neutralising the activity of a protein called IL-23. IL-23 is present in increased levels in people with psoriatic arthritis and psoriasis. IL-23 can cause pain and swelling in the joints. Guselkumab is called an IL-23 inhibitor.
Guselkumab is used to treat adults with active psoriatic arthritis, an inflammatory disease of the joints in which psoriasis usually occurs with arthritis. It is also used to treat adults with moderate to severe plaque psoriasis, an inflammatory condition affecting the skin and nails.
Guselkumab may be used with other arthritis medicines including:
Guselkumab cannot be used with other bDMARDs.
There are separate information sheets for the medicines mentioned above.
You might experience side effects with your treatment. Contact your rheumatologist if you have any concerns about possible side effects. Many side effects disappear when guselkumab treatment is stopped.
Most common possible side effects
Less common or rare possible side effects
There are some rare but potentially serious side effects with guselkumab
Other side effects not listed in this leaflet may also occur. Tell your doctor if you notice any other side effects that you think might be caused by guselkumab.
Use with other medicines
For more information on vaccination including the COVID-19 vaccination go to the Vaccinations page on the ARA website
Use with alcohol
Use in pregnancy and when breastfeeding